 |
PDBsum entry 1os5
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase
|
 |
|
Title:
|
 |
Crystal structure of hcv ns5b RNA polymerase complexed with a novel non-competitive inhibitor.
|
|
Structure:
|
 |
Hepatitis c virus ns5b RNA polymerase. Chain: a. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Hepatitis c virus. Organism_taxid: 31647. Strain: subtype 1b. Gene: ns5b. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Resolution:
|
 |
|
2.20Å
|
R-factor:
|
0.207
|
R-free:
|
0.251
|
|
|
Authors:
|
 |
R.A.Love,H.E.Parge,X.Yu,M.J.Hickey,W.Diehl,J.Gao,H.Wriggers,A.Ekker, L.Wang,J.A.Thomson,P.S.Dragovich,S.A.Fuhrman
|
|
Key ref:
|
 |
R.A.Love
et al.
(2003).
Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme.
J Virol,
77,
7575-7581.
PubMed id:
|
 |
|
Date:
|
 |
|
18-Mar-03
|
Release date:
|
18-Mar-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P26663
(POLG_HCVBK) -
Genome polyprotein from Hepatitis C virus genotype 1b (isolate BK)
|
|
|
|
Seq: Struc:
|
 |
 |
 |
3010 a.a.
563 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 4 residue positions (black
crosses)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
E.C.2.7.7.48
- RNA-directed Rna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
RNA(n) + a ribonucleoside 5'-triphosphate = RNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
RNA(n)
|
+
|
ribonucleoside 5'-triphosphate
|
=
|
RNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.3.4.21.98
- hepacivirin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Hydrolysis of four peptide bonds in the viral precursor polyprotein, commonly with Asp or Glu in the P6 position, Cys or Thr in P1 and Ser or Ala in P1'.
|
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
E.C.3.4.22.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
E.C.3.6.1.15
- nucleoside-triphosphate phosphatase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a ribonucleoside 5'-triphosphate + H2O = a ribonucleoside 5'-diphosphate + phosphate + H+
|
 |
 |
 |
 |
 |
ribonucleoside 5'-triphosphate
|
+
|
H2O
|
=
|
ribonucleoside 5'-diphosphate
|
+
|
phosphate
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 5:
|
 |
E.C.3.6.4.13
- Rna helicase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
ATP + H2O = ADP + phosphate + H+
|
 |
 |
 |
 |
 |
ATP
|
+
|
H2O
|
=
|
ADP
|
+
|
phosphate
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
|
J Virol
77:7575-7581
(2003)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme.
|
|
R.A.Love,
H.E.Parge,
X.Yu,
M.J.Hickey,
W.Diehl,
J.Gao,
H.Wriggers,
A.Ekker,
L.Wang,
J.A.Thomson,
P.S.Dragovich,
S.A.Fuhrman.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The virus-encoded nonstructural protein 5B (NS5B) of hepatitis C virus (HCV) is
an RNA-dependent RNA polymerase and is absolutely required for replication of
the virus. NS5B exhibits significant differences from cellular polymerases and
therefore has become an attractive target for anti-HCV therapy. Using a
high-throughput screen, we discovered a novel NS5B inhibitor that binds to the
enzyme noncompetitively with respect to nucleotide substrates. Here we report
the crystal structure of NS5B complexed with this small molecule inhibitor.
Unexpectedly, the inhibitor is bound within a narrow cleft on the protein's
surface in the "thumb" domain, about 30 A from the enzyme's catalytic center.
The interaction between this inhibitor and NS5B occurs without dramatic changes
to the structure of the protein, and sequence analysis suggests that the binding
site is conserved across known HCV genotypes. Possible mechanisms of inhibition
include perturbation of protein dynamics, interference with RNA binding, and
disruption of enzyme oligomerization.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.H.Lee,
S.Lee,
M.Y.Park,
and
H.Myung
(2011).
Characterization of thiobarbituric acid derivatives as inhibitors of hepatitis C virus NS5B polymerase.
|
| |
Virol J,
8,
18.
|
 |
|
|
|
|
 |
P.Clemente-Casares,
A.J.López-Jiménez,
I.Bellón-Echeverría,
J.A.Encinar,
E.Martínez-Alfaro,
R.Pérez-Flores,
and
A.Mas
(2011).
De novo polymerase activity and oligomerization of hepatitis C virus RNA-dependent RNA-polymerases from genotypes 1 to 5.
|
| |
PLoS One,
6,
e18515.
|
 |
|
|
|
|
 |
O.Nyanguile,
B.Devogelaere,
L.Vijgen,
W.Van den Broeck,
F.Pauwels,
M.D.Cummings,
H.L.De Bondt,
A.M.Vos,
J.M.Berke,
O.Lenz,
G.Vandercruyssen,
K.Vermeiren,
W.Mostmans,
P.Dehertogh,
F.Delouvroy,
S.Vendeville,
K.VanDyck,
K.Dockx,
E.Cleiren,
P.Raboisson,
K.A.Simmen,
and
G.C.Fanning
(2010).
1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.
|
| |
J Virol,
84,
2923-2934.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.C.Durk,
K.Singh,
C.A.Cornelison,
D.K.Rai,
K.B.Matzek,
M.D.Leslie,
E.Schafer,
B.Marchand,
A.Adedeji,
E.Michailidis,
C.A.Dorst,
J.Moran,
C.Pautler,
L.L.Rodriguez,
M.A.McIntosh,
E.Rieder,
and
S.G.Sarafianos
(2010).
Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase.
|
| |
PLoS One,
5,
e15049.
|
 |
|
|
|
|
 |
S.S.Carroll,
S.Ludmerer,
L.Handt,
K.Koeplinger,
N.R.Zhang,
D.Graham,
M.E.Davies,
M.MacCoss,
D.Hazuda,
and
D.B.Olsen
(2009).
Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees.
|
| |
Antimicrob Agents Chemother,
53,
926-934.
|
 |
|
|
|
|
 |
S.T.Shi,
K.J.Herlihy,
J.P.Graham,
J.Nonomiya,
S.V.Rahavendran,
H.Skor,
R.Irvine,
S.Binford,
J.Tatlock,
H.Li,
J.Gonzalez,
A.Linton,
A.K.Patick,
and
C.Lewis
(2009).
Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
|
| |
Antimicrob Agents Chemother,
53,
2544-2552.
|
 |
|
|
|
|
 |
A.Y.Howe,
H.Cheng,
S.Johann,
S.Mullen,
S.K.Chunduru,
D.C.Young,
J.Bard,
R.Chopra,
G.Krishnamurthy,
T.Mansour,
and
J.O'Connell
(2008).
Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
|
| |
Antimicrob Agents Chemother,
52,
3327-3338.
|
 |
|
|
|
|
 |
G.Koev,
and
W.Kati
(2008).
The emerging field of HCV drug resistance.
|
| |
Expert Opin Investig Drugs,
17,
303-319.
|
 |
|
|
|
|
 |
K.J.Herlihy,
J.P.Graham,
R.Kumpf,
A.K.Patick,
R.Duggal,
and
S.T.Shi
(2008).
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
|
| |
Antimicrob Agents Chemother,
52,
3523-3531.
|
 |
|
|
|
|
 |
K.K.Ng,
J.J.Arnold,
and
C.E.Cameron
(2008).
Structure-function relationships among RNA-dependent RNA polymerases.
|
| |
Curr Top Microbiol Immunol,
320,
137-156.
|
 |
|
|
|
|
 |
M.Hass,
M.Lelke,
C.Busch,
B.Becker-Ziaja,
and
S.Günther
(2008).
Mutational evidence for a structural model of the Lassa virus RNA polymerase domain and identification of two residues, Gly1394 and Asp1395, that are critical for transcription but not replication of the genome.
|
| |
J Virol,
82,
10207-10217.
|
 |
|
|
|
|
 |
M.Mazzei,
E.Nieddu,
M.Miele,
A.Balbi,
M.Ferrone,
M.Fermeglia,
M.T.Mazzei,
S.Pricl,
P.La Colla,
F.Marongiu,
C.Ibba,
and
R.Loddo
(2008).
Activity of Mannich bases of 7-hydroxycoumarin against Flaviviridae.
|
| |
Bioorg Med Chem,
16,
2591-2605.
|
 |
|
|
|
|
 |
N.Kaushik-Basu,
A.Bopda-Waffo,
T.T.Talele,
A.Basu,
P.R.Costa,
A.J.da Silva,
S.G.Sarafianos,
and
F.Noël
(2008).
Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors.
|
| |
Nucleic Acids Res,
36,
1482-1496.
|
 |
|
|
|
|
 |
S.T.Shi,
K.J.Herlihy,
J.P.Graham,
S.A.Fuhrman,
C.Doan,
H.Parge,
M.Hickey,
J.Gao,
X.Yu,
F.Chau,
J.Gonzalez,
H.Li,
C.Lewis,
A.K.Patick,
and
R.Duggal
(2008).
In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase.
|
| |
Antimicrob Agents Chemother,
52,
675-683.
|
 |
|
|
|
|
 |
E.De Clercq
(2007).
The design of drugs for HIV and HCV.
|
| |
Nat Rev Drug Discov,
6,
1001-1018.
|
 |
|
|
|
|
 |
F.Fernandes,
D.S.Poole,
S.Hoover,
R.Middleton,
A.C.Andrei,
J.Gerstner,
and
R.Striker
(2007).
Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B.
|
| |
Hepatology,
46,
1026-1033.
|
 |
|
|
|
|
 |
F.Pauwels,
W.Mostmans,
L.M.Quirynen,
L.van der Helm,
C.W.Boutton,
A.S.Rueff,
E.Cleiren,
P.Raboisson,
D.Surleraux,
O.Nyanguile,
and
K.A.Simmen
(2007).
Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors.
|
| |
J Virol,
81,
6909-6919.
|
 |
|
|
|
|
 |
W.Hao,
K.J.Herlihy,
N.J.Zhang,
S.A.Fuhrman,
C.Doan,
A.K.Patick,
and
R.Duggal
(2007).
Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening.
|
| |
Antimicrob Agents Chemother,
51,
95.
|
 |
|
|
|
|
 |
A.Y.Howe,
H.Cheng,
I.Thompson,
S.K.Chunduru,
S.Herrmann,
J.O'Connell,
A.Agarwal,
R.Chopra,
and
A.M.Del Vecchio
(2006).
Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.
|
| |
Antimicrob Agents Chemother,
50,
4103-4113.
|
 |
|
|
|
|
 |
D.E.Danley
(2006).
Crystallization to obtain protein-ligand complexes for structure-aided drug design.
|
| |
Acta Crystallogr D Biol Crystallogr,
62,
569-575.
|
 |
|
|
|
|
 |
J.Ortín,
and
F.Parra
(2006).
Structure and function of RNA replication.
|
| |
Annu Rev Microbiol,
60,
305-326.
|
 |
|
|
|
|
 |
S.Le Pogam,
H.Kang,
S.F.Harris,
V.Leveque,
A.M.Giannetti,
S.Ali,
W.R.Jiang,
S.Rajyaguru,
G.Tavares,
C.Oshiro,
T.Hendricks,
K.Klumpp,
J.Symons,
M.F.Browner,
N.Cammack,
and
I.Nájera
(2006).
Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.
|
| |
J Virol,
80,
6146-6154.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
H.Ma,
V.Leveque,
A.De Witte,
W.Li,
T.Hendricks,
S.M.Clausen,
N.Cammack,
and
K.Klumpp
(2005).
Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors.
|
| |
Virology,
332,
8.
|
 |
|
|
|
|
 |
H.Mo,
L.Lu,
T.Pilot-Matias,
R.Pithawalla,
R.Mondal,
S.Masse,
T.Dekhtyar,
T.Ng,
G.Koev,
V.Stoll,
K.D.Stewart,
J.Pratt,
P.Donner,
T.Rockway,
C.Maring,
and
A.Molla
(2005).
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.
|
| |
Antimicrob Agents Chemother,
49,
4305-4314.
|
 |
|
|
|
|
 |
J.E.Tomassini,
K.Getty,
M.W.Stahlhut,
S.Shim,
B.Bhat,
A.B.Eldrup,
T.P.Prakash,
S.S.Carroll,
O.Flores,
M.MacCoss,
D.R.McMasters,
G.Migliaccio,
and
D.B.Olsen
(2005).
Inhibitory effect of 2'-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells.
|
| |
Antimicrob Agents Chemother,
49,
2050-2058.
|
 |
|
|
|
|
 |
R.De Francesco,
and
G.Migliaccio
(2005).
Challenges and successes in developing new therapies for hepatitis C.
|
| |
Nature,
436,
953-960.
|
 |
|
|
|
|
 |
S.W.Ludmerer,
D.J.Graham,
E.Boots,
E.M.Murray,
A.Simcoe,
E.J.Markel,
J.A.Grobler,
O.A.Flores,
D.B.Olsen,
D.J.Hazuda,
and
R.L.LaFemina
(2005).
Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.
|
| |
Antimicrob Agents Chemother,
49,
2059-2069.
|
 |
|
|
|
|
 |
G.McKercher,
P.L.Beaulieu,
D.Lamarre,
S.LaPlante,
S.Lefebvre,
C.Pellerin,
L.Thauvette,
and
G.Kukolj
(2004).
Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate.
|
| |
Nucleic Acids Res,
32,
422-431.
|
 |
|
|
|
|
 |
L.Tomei,
S.Altamura,
L.Bartholomew,
M.Bisbocci,
C.Bailey,
M.Bosserman,
A.Cellucci,
E.Forte,
I.Incitti,
L.Orsatti,
U.Koch,
R.De Francesco,
D.B.Olsen,
S.S.Carroll,
and
G.Migliaccio
(2004).
Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.
|
| |
J Virol,
78,
938-946.
|
 |
|
|
|
|
 |
R.A.Love,
K.A.Maegley,
X.Yu,
R.A.Ferre,
L.K.Lingardo,
W.Diehl,
H.E.Parge,
P.S.Dragovich,
and
S.A.Fuhrman
(2004).
The crystal structure of the RNA-dependent RNA polymerase from human rhinovirus: a dual function target for common cold antiviral therapy.
|
| |
Structure,
12,
1533-1544.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
V.Brass,
H.E.Blum,
and
D.Moradpour
(2004).
Recent developments in target identification against hepatitis C virus.
|
| |
Expert Opin Ther Targets,
8,
295-307.
|
 |
|
|
|
|
 |
L.Tomei,
S.Altamura,
L.Bartholomew,
A.Biroccio,
A.Ceccacci,
L.Pacini,
F.Narjes,
N.Gennari,
M.Bisbocci,
I.Incitti,
L.Orsatti,
S.Harper,
I.Stansfield,
M.Rowley,
R.De Francesco,
and
G.Migliaccio
(2003).
Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
|
| |
J Virol,
77,
13225-13231.
|
 |
|
|
|
|
 |
X.Xu,
Y.Liu,
S.Weiss,
E.Arnold,
S.G.Sarafianos,
and
J.Ding
(2003).
Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design.
|
| |
Nucleic Acids Res,
31,
7117-7130.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |